Sign in
CompletedNo phase

Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
100 people enrolled
Started
15 Dec 2023
Ended
15 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Other (Conventional Therapy)
  • Fiberoptic Bronchoscopy
Record updated
2 September 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults aged 18-65 years
  • Patients of both sexes
  • Patients requiring mechanical ventilation
  • Development of pneumonia ≥ 48 hours after endotracheal intubation or ≥ 48 hours after extubation
  • Diagnosis of severe ventilator-associated pneumonia defined by a Modified Clinical Pulmonary Infection Score (CPIS) > 6

Who cannot take part

  • Presence of lung shadows prior to mechanical ventilation
  • Severe bleeding disorders or immune system diseases
  • Recent myocardial infarction or unstable arrhythmia
  • Refusal to participate
  • Severe hemodynamic instability
  • Tracheal stenosis or upper airway mass

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled trial evaluated the clinical effect of fiberoptic bronchoscopy in the management of adult patients with severe ventilator-associated pneumonia (VAP). A total of 100 patients admitted to the Critical Care Department at Benha University Hospitals were enrolled and randomly assigned in equal numbers to two groups. The control group received standard therapy, including culture-guided antibiotics, lavage, and aspiration. The intervention group received the same treatment plus fiberoptic bronchoscopy for secretion clearance, lavage, and culture-directed antibiotic therapy.

Read full original descriptionShow less

The primary outcome was the overall effective treatment rate, defined as the proportion of patients with significant or partial clinical improvement. Secondary outcomes included recovery time, length of intensive care unit stay, respiratory mechanics, inflammatory markers (C-reactive protein and procalcitonin), recurrence of pulmonary infection, and 28-day mortality.

The study demonstrated whether the addition of fiberoptic bronchoscopy to conventional treatment improved clinical outcomes in patients with severe ventilator-associated pneumonia.

The 2 groups in the trial

  • Control GroupExisting treatment, for comparison

    Participants received standard therapy for severe ventilator-associated pneumonia, which included culture-guided antibiotics, routine drug therapy, tracheal lavage, and aspiration. Sputum samples were collected for bacterial culture and sensitivity testing to guide antibiotic selection.

    Treatment: Other (Conventional Therapy)

  • Fiberoptic Bronchoscopy GroupTreatment being tested

    Participants received the same standard therapy as the control group plus fiberoptic bronchoscopy. The bronchoscope was inserted via the endotracheal tube to clear secretions, obtain samples for culture, and perform bronchoscopic alveolar lavage. Lavage was performed once daily for one week using sterile sodium chloride solution with ambroxol hydrochloride, followed by antibiotic administration. Cultures were used to guide therapy.

    Treatment: Fiberoptic Bronchoscopy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Clinical Effect of Fiberoptic Bronchoscopy in Management of Adult Patients With Severe Ventilator-associated Pneumonia; a Randomized Controlled Trial
Record updated
2 September 2025